Q-omics provides the consensus-scored MCF2L2 profile across patient tissues and cancer cell-line models. MCF2L2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MCF2L2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MCF2L2 RNA expression shows 18,936 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where MCF2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCF2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCF2L2 survival associations across molecular data types. MCF2L2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCF2L2 RNA expression–survival associations across cancer types. High MCF2L2 expression shows unfavorable associations in MESO, KIRC, UCEC and UVM, but favorable associations in SCLC and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MCF2L2 RNA expression.
This table summarizes MCF2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MCF2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCF2L2 shows lower tumor expression in COAD and KIRC and higher tumor expression in HNSC, THCA, LUSC and LIHC. The HNSC box plot shows higher MCF2L2 RNA expression in tumor versus normal tissue (log2 FC = +0.181, t-test p < 0.001).
This table shows molecular features associated with MCF2L2 in patient tissues and cancer cell lines. In patient samples, MCF2L2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MCF2L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
